However, the combination of Merck's approved doravirine and investigational islatravir didn't prove superiority over Gilead's ...

The global cancer vaccines market, valued at US$10.23 billion in 2023, is forecasted to grow at a robust CAGR of 8.6%, ...

Physicians, nurse practitioners, or physician assistants prescribed medication to patients with OUD, while intervention ...

A new antibody from Merck would join a market teeming with new entries, but plenty of regulatory and financial uncertainty.

DelveInsight's Germ Cell Tumors Market Insights report includes a comprehensive understanding of current treatment practices, ...

Title: GOBLET platform study: Preliminary safety and tumor response results for the relapsed anal carcinoma cohort in patients treated with pelareorep and atezolizumab. Session Title: Poster Session C ...

AnaptysBio's rosnilimab faces significant competition and uncertainty. See why ANAB stock's future hinges on Feb 2025 Phase ...